Rezpegaldesleukin

Phase 3Protein / enzyme

NNektar Therapeutics

Rezpegaldesleukin is one of 104 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

Alopecia AreataActive, not recruiting

Moderate to Severe Atopic DermatitisRecruiting

Type 1 Diabetes MellitusActive, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Alopecia AreataPhase 2

Active, not recruiting

Moderate to Severe Atopic DermatitisPhase 3

Recruiting

Type 1 Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Skyrizi

AbbVie

Phase 3

2 2

Cytosar

Teva

Phase 3

1 3

Eucrisa

AAnacor

Phase 3

4 4

Amlitelimab

Sanofi

Phase 3

6 5

Calcineurin Inhibitors

Sanofi

Phase 3

1 6

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

4 7

Pegcrisantaspase

Jazz Pharmaceuticals

Phase 3

1 8

Rezpegaldesleukin

NNektar Therapeutics

Phase 3

1 9

EBGLYSS

Cibinqo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Alopecia Areata

NCT06340360

Q4 2026

Phase 2Active, not recruiting

Atopic Dermatitis

NCT06136741

Q4 2028

Phase 3Recruiting

Moderate to Severe Atopic Dermatitis

NCT07690371

Q2 2029

Phase 2Not yet recruiting

Type 1 Diabetes Mellitus

NCT07142252

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting·NNektar Therapeutics·Phase 2·NCT06136741·396 enrolled

Type 1 Diabetes Mellitus1 trial

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Not yet recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT07142252·66 enrolled

Alopecia Areata1 trial

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Active, not recruiting·NNektar Therapeutics·Phase 2·NCT06340360·94 enrolled

Moderate to Severe Atopic Dermatitis1 trial

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting·NNektar Therapeutics·Phase 3·NCT07690371·510 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Rezpegaldesleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rezpegaldesleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rezpegaldesleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nektar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: NNektar Therapeutics

Rezpegaldesleukin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2028

Q2 2029

Trials by Indication[1]

Atopic Dermatitis1 trial

Type 1 Diabetes Mellitus1 trial

Alopecia Areata1 trial

Moderate to Severe Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News